Table 2.
Cumulative incidence of cause-specific death and Gray's test in the whole cohort.
| Characteristics | Death from CVD (%) | P | Death from BC (%) | P | Death from non-CVD (%) | P | |||
|---|---|---|---|---|---|---|---|---|---|
| 5-years | 10-years | 5-years | 10-years | 5-years | 10-years | ||||
| Total | 7.8 | 13.5 | 21.3 | 24.8 | 8.3 | 15.1 | |||
| Age (years) | <0.001 | <0.001 | <0.001 | ||||||
| <65 | 2.0 | 3.9 | 15.9 | 18.2 | 3.1 | 5.8 | |||
| 65–74 | 5.6 | 11.0 | 18.5 | 22.2 | 7.0 | 14.1 | |||
| 75–84 | 11.7 | 20.8 | 24.8 | 29.3 | 12.0 | 22.9 | |||
| ≥85 | 20.4 | 29.4 | 35.4 | 38.7 | 17.5 | 25.4 | |||
| Sex | <0.001 | <0.001 | <0.001 | ||||||
| Male | 8.3 | 14.3 | 19.8 | 23.3 | 8.6 | 15.5 | |||
| Female | 6.4 | 11.3 | 25.8 | 28.8 | 7.5 | 13.9 | |||
| Race | <0.001 | <0.001 | <0.001 | ||||||
| White | 8.0 | 13.8 | 20.7 | 24.1 | 8.4 | 15.3 | |||
| Black | 6.9 | 11.0 | 33.3 | 37.1 | 7.7 | 12.7 | |||
| Others | 5.6 | 10.1 | 20.7 | 23.9 | 7.2 | 13.0 | |||
| Marital status | <0.001 | <0.001 | <0.001 | ||||||
| Married | 7.0 | 12.4 | 17.9 | 21.3 | 7.2 | 13.7 | |||
| Single/other | 9.4 | 15.3 | 27.1 | 30.6 | 10.3 | 17.4 | |||
| Primary site | <0.001 | <0.001 | <0.001 | ||||||
| C67.0-Trigone of bladder | 7.5 | 13.7 | 20.8 | 23.8 | 7.7 | 14.0 | |||
| C67.1-Dome of bladder | 8.4 | 14.2 | 27.1 | 30.7 | 8.5 | 15.6 | |||
| C67.2-Lateral wall of bladder | 7.4 | 13.7 | 14.9 | 17.8 | 8.3 | 15.0 | |||
| C67.3-Anterior wall of bladder | 9.0 | 15.4 | 26.2 | 29.5 | 9.6 | 16.1 | |||
| C67.4-Posterior wall of bladder | 8.6 | 15.1 | 16.4 | 19.6 | 8.7 | 16.4 | |||
| C67.5-Bladder neck | 8.8 | 14.6 | 24.3 | 27.2 | 8.1 | 14.1 | |||
| C67.6-Ureteric orifice | 6.9 | 13.0 | 10.3 | 13.1 | 7.3 | 14.4 | |||
| C67.7-Urachus | 2.4 | 3.2 | 37.3 | 45.5 | 4.1 | 6.4 | |||
| C67.8-Overlapping lesion of bladder | 8.2 | 12.9 | 32.5 | 36.3 | 8.7 | 14.8 | |||
| C67.9-Bladder, NOS | 7.8 | 12.9 | 23.0 | 26.9 | 8.3 | 15.2 | |||
| Histologic type | <0.001 | <0.001 | <0.001 | ||||||
| Transitional cell carcinoma | 8.0 | 13.7 | 19.9 | 23.4 | 8.4 | 15.3 | |||
| Squamous cell carcinoma | 5.6 | 8.7 | 51.6 | 53.5 | 8.0 | 12.2 | |||
| Adenocarcinoma | 5.6 | 7.8 | 52.1 | 57.1 | 7.0 | 8.3 | |||
| Other and Unclassified carcinoma | 5.1 | 7.2 | 60.1 | 63.4 | 6.6 | 9.8 | |||
| Tumor grade | <0.001 | <0.001 | <0.001 | ||||||
| I | 7.4 | 14.2 | 4.3 | 6.7 | 8.1 | 16.4 | |||
| II | 7.8 | 14.6 | 6.8 | 9.9 | 8.1 | 16.1 | |||
| III | 8.4 | 13.3 | 34.9 | 38.8 | 8.8 | 14.5 | |||
| IV | 7.7 | 12.2 | 33.9 | 38.2 | 8.3 | 13.9 | |||
| Summary stage | <0.001 | <0.001 | <0.001 | ||||||
| In situ | 7.8 | 14.9 | 3.6 | 6.1 | 8.2 | 16.6 | |||
| Localized | 8.9 | 14.2 | 26.8 | 31.6 | 9.4 | 15.7 | |||
| Regional | 5.4 | 7.6 | 60.1 | 63.9 | 6.5 | 9.2 | |||
| Distant | 3.1 | 3.4 | 87.4 | 88.5 | 4.3 | 4.9 | |||
| Surgery | 0.08 | <0.001 | 0.03 | ||||||
| No | 8.3 | 12.7 | 34.7 | 36.8 | 8.4 | 13.6 | |||
| Yes | 7.8 | 13.5 | 20.8 | 24.3 | 8.3 | 15.2 | |||
| Radiotherapy | <0.001 | <0.001 | <0.001 | ||||||
| No | 7.8 | 13.6 | 18.7 | 22.1 | 8.3 | 15.3 | |||
| Yes | 8.8 | 11.5 | 63.0 | 66.9 | 8.8 | 11.9 | |||
| Chemotherapy | <0.001 | <0.001 | <0.001 | ||||||
| No | 8.5 | 14.4 | 17.9 | 21.2 | 8.8 | 15.9 | |||
| Yes | 5.4 | 9.8 | 34.2 | 38.6 | 6.4 | 11.7 | |||